Nectar Lifesciences Approves ₹120 Crore Loan to New Real Estate Subsidiary

Nectar Lifesciences Limited's board has sanctioned a significant inter-corporate loan of up to ₹120 crore. This capital is earmarked for Avensis Exports Private Limited, the company's newly acquired wholly-owned subsidiary.

The company also issued an apology for a delay in providing these details, attributing it to an administrative oversight.

What just happened (today’s filing)

Nectar Lifesciences Limited's board of directors, in a meeting on March 02, 2026, approved an inter-corporate loan of up to ₹120.00 crore.

This funding is intended for Avensis Exports Private Limited, which was recently acquired by Nectar Lifesciences.

The company acknowledged a prior delay in disclosing this information, citing administrative oversight and offering an apology.

Why this matters

This move signifies a strategic capital infusion into a newly acquired entity, Avensis Exports, which is poised to facilitate Nectar Lifesciences' diversification into the real estate sector.

It highlights the deployment of funds to support the operationalization and growth plans of this new venture, potentially unlocking new revenue streams for the company.

The backstory (grounded)

Nectar Lifesciences, a research-driven pharmaceutical company, manufactures APIs, intermediates, and finished dosage forms, with a specialization in Cephalosporins. It also has interests in menthol, capsules, and contract manufacturing.

On March 2, 2026, Nectar Lifesciences acquired 100% of Avensis Exports Private Limited for ₹24.96 lakh, marking its strategic entry into real estate. Notably, Avensis Exports reported zero turnover for the past three financial years.

The company has been focusing on improving its financial health, evidenced by a reduced debt-to-equity ratio of 0.61 as of March 2025.

However, the company faced financial headwinds in FY25, reporting revenue of approximately ₹1,673 crore and a PBILDT loss of about ₹26 crore, exacerbated by an inventory write-down.

Nectar Lifesciences also recently completed a share buyback, extinguishing 3 crore shares for ₹81 crore.

What changes now

• Avensis Exports Private Limited, the newly acquired subsidiary, will receive substantial capital to support its operations and real estate ventures.
• Nectar Lifesciences signals a strategic diversification beyond its core pharmaceutical business.
• Shareholders gain clarity on the allocation of funds towards subsidiary development following the acquisition.

Risks to watch

• The stated delay in disclosing the loan approval, attributed to administrative oversight, could point to potential procedural or communication inefficiencies. [cite: Input]
• Nectar Lifesciences is involved in significant litigation concerning GST and Input Tax Credit claims, which could lead to substantial financial liabilities.
• The company's recent financial performance in FY25 showed an operating loss and challenges, despite revenue stability.
• The acquisition of Avensis Exports, a subsidiary with zero turnover, presents execution risk in establishing a new business vertical.

Peer comparison

Nectar Lifesciences operates in a competitive landscape. Peers like Divi's Laboratories and Sun Pharmaceutical Industries, India's largest pharma entity, are established players often engaging in significant capital allocation for R&D and expansion. Ipca Laboratories and Granules India are also key players in APIs and formulations. While these peers focus on their core pharmaceutical growth, Nectar's move into real estate via a subsidiary with substantial funding highlights a diversification strategy.

Context metrics (time-bound)

• Nectar Lifesciences reported a PBILDT loss of ₹-26.46 crore for the fiscal year ending March 2025.
• The company's revenue for the fiscal year ending March 2025 was ₹1,673.08 crore.

What to track next

• Finalization and disclosure of the definitive loan agreement with Avensis Exports.
• The performance and strategic execution of Avensis Exports in the real estate sector.
• Future financial results of Nectar Lifesciences, particularly regarding profitability and the impact of its diversification efforts.
• Updates on the ongoing GST/ITC litigation and its potential financial outcomes.
• Subsequent disclosures regarding the subsidiary's operational activities.